SpringerLink
Log in

Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients

  • Geriatric Oncology (AR MacKenzie, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Acute myeloid leukemia (AML) disproportionately impacts elderly patients. Treating elderly patients with AML has been a challenge due to the increased prevalence of medical comorbidities and decreased performance status in this population, as well as the different biology of AML in elderly patients.

Recent Findings

The care of elderly patients with AML has advanced significantly over the past few years. Our greater understanding of the biology of AML in elderly patients has led to the development of novel, lower-intensity treatment options. We present here a review of the most recent literature regarding therapeutic options available to older patients, as well as tools to help identify the right treatment for the right patient.

Summary

As targeted and lower-intensity treatment options become available, develo** an approach to “right size” therapy for individual elderly patients is paramount.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. National Cancer Institute. Cancer stat facts. https://seer.cancer.gov/statfacts/html/amyl.html. Updated 2018. Accessed 2/8, 2019.

  2. Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–74. https://doi.org/10.1182/blood-2014-08-551499.

    Article  CAS  PubMed  Google Scholar 

  3. Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541–52.

    Article  Google Scholar 

  4. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624–7.

    Article  Google Scholar 

  5. Savic A, Kvrgic V, Rajic N, Urosevic I, Kovacevic D, Percic I, et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36(4):479–82. https://doi.org/10.1016/j.leukres.2011.11.021.

    Article  Google Scholar 

  6. Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–8. https://doi.org/10.1016/S0140-6736(10)62105-8.

    Article  CAS  PubMed  Google Scholar 

  7. Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32(15):1586–94. https://doi.org/10.1200/JCO.2013.52.3480.

    Article  Google Scholar 

  8. Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43–62.

    Article  Google Scholar 

  9. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287–94. https://doi.org/10.1182/blood-2012-12-471680.

    Article  CAS  Google Scholar 

  10. National Institutes of Health National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01188330?term=geriatric+assessment&cond=aml&rank=1. Updated 2019. Accessed February 8, 2019.

  11. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–5.

    Article  CAS  Google Scholar 

  12. Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821–30. https://doi.org/10.1002/cncr.30220.

    Article  CAS  Google Scholar 

  13. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791–7. https://doi.org/10.1200/JCO.2008.16.0259.

    Article  PubMed  Google Scholar 

  14. Papaemmanuil E, Dohner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900–1. https://doi.org/10.1056/NEJMc1608739. This landmark publication is on the forefront of our understanding of molecular aberrations in AML. While the focus here is not specifically on elderly patients, this article highlights many of the aberrations which may underlie the changing biology of AML overtime.

    Article  PubMed  Google Scholar 

  15. Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol. 2012;91(1):9–18. https://doi.org/10.1007/s00277-011-1280-6.

    Article  Google Scholar 

  16. Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, et al. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia. Eur J Haematol. 2008;80(3):208–15 doi: EJH1019 [pii.

  17. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood. 2011;118(26):6920–9. https://doi.org/10.1182/blood-2011-08-368225.

    Article  CAS  Google Scholar 

  18. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803–10. https://doi.org/10.1182/blood-2011-02-339747.

    Article  CAS  Google Scholar 

  19. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–33. https://doi.org/10.1056/NEJMoa1005143.

    Article  CAS  Google Scholar 

  20. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–76. https://doi.org/10.1182/blood-2014-11-610543.

    Article  Google Scholar 

  21. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9. https://doi.org/10.1182/blood-2015-01-621664.

    Article  CAS  Google Scholar 

  22. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the swedish acute leukemia registry. Blood. 2009;113(18):4179–87. https://doi.org/10.1182/blood-2008-07-172007.

    Article  Google Scholar 

  23. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the european organization for research and treatment of cancer leukemia group. J Clin Oncol. 1989;7(9):1268–74. https://doi.org/10.1200/JCO.1989.7.9.1268.

    Article  CAS  PubMed  Google Scholar 

  24. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–24. https://doi.org/10.3324/haematol.2012.066100.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–48. https://doi.org/10.1056/NEJMoa0901409.

    Article  PubMed  Google Scholar 

  26. Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–46. https://doi.org/10.1182/blood-2013-12-540971.

    Article  CAS  Google Scholar 

  27. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–92. https://doi.org/10.1200/JCO.2017.77.6112. Treatment with Vyxeos is an important part of induction for secondary- and treatment-related AML which appears to be better tolerated than standard induction therapy.

    Article  CAS  Google Scholar 

  28. Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018;132(10):1007–12. https://doi.org/10.1182/blood-2018-03-828269. Preliminary clinical efficacy of venetoclax in combination with hypomethylating agents highlights the unexpected importance of the BCL-2 pathway in the treatment of AML. Many studies are now ongoing evaluating BCL-2 inhibition in combination with other treatment strategies.

    Article  CAS  PubMed  Google Scholar 

  29. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–28.

    Article  CAS  Google Scholar 

  30. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. https://doi.org/10.1182/blood-2018-08-868752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. National Institutes of Health National Library of Medicine. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?cond=Aml&term=venetoclax&cntry=&state=&city=&dist=. Updated 2019. Accessed February 11, 2019.

  32. U.S. Food and Drug Administration. Https://Www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555756.htm. . Updated 2017. Accessed March 6, 2019.

  33. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. https://doi.org/10.1056/NEJMoa1614359.

    Article  CAS  Google Scholar 

  34. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556–61. https://doi.org/10.1200/JCO.2009.23.9178.

    Article  CAS  PubMed  Google Scholar 

  35. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7. https://doi.org/10.1200/JCO.2011.38.9429.

    Article  CAS  Google Scholar 

  36. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–24. https://doi.org/10.1002/cncr.22496.

    Article  CAS  Google Scholar 

  37. Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001;1(5):893–901. https://doi.org/10.1517/14712598.1.5.893.

    Article  CAS  PubMed  Google Scholar 

  38. Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005;29(1):53–7.

    Article  CAS  Google Scholar 

  39. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia. 2005;19(10):1768–73.

    Article  CAS  Google Scholar 

  40. Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J Clin Oncol. 2016;34(9):972–9. https://doi.org/10.1200/JCO.2015.64.0060.

    Article  Google Scholar 

  41. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27(1):75–81. https://doi.org/10.1038/leu.2012.229.

    Article  CAS  PubMed  Google Scholar 

  42. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96. https://doi.org/10.1016/S1470-2045(14)70281-5.

    Article  CAS  Google Scholar 

  43. Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, et al. A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood. 2013;122(20):3432–9. https://doi.org/10.1182/blood-2013-06-506592.

    Article  CAS  Google Scholar 

  44. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98. https://doi.org/10.1056/NEJMoa1716984. Treatment with IDH1-inhibitors represents the growing trend toward well-tolerated, targeted therapies in AML.

    Article  CAS  PubMed  Google Scholar 

  45. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31. https://doi.org/10.1182/blood-2017-04-779405. Treatment with IDH2-inhibitors represents the growing trend toward well-tolerated, targeted therapies in AML.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thomas Jefferson University Hospital, 834 Chestnut St, Suite 315, Philadelphia, PA, 19107, USA

    Gina Keiffer & Neil Palmisiano

Authors
  1. Gina Keiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Palmisiano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gina Keiffer.

Ethics declarations

Conflict of Interest

Gina Keiffer declares that she has no conflict of interest.

Neil Palmisiano has received research funding support from AbbVie.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Geriatric Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keiffer, G., Palmisiano, N. Acute Myeloid Leukemia: Update on Upfront Therapy in Elderly Patients. Curr Oncol Rep 21, 71 (2019). https://doi.org/10.1007/s11912-019-0823-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0823-1

Keywords

Search

Navigation